181 related articles for article (PubMed ID: 31783245)
1. Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation.
Quinn MH; Bauer AM; Flitter A; Lubitz SF; Ashare RL; Thompson M; Leone F; Gross R; Schnoll R
Addict Behav; 2020 Mar; 102():106151. PubMed ID: 31783245
[TBL] [Abstract][Full Text] [Related]
2. Medication adherence and rate of nicotine metabolism are associated with response to treatment with varenicline among smokers with HIV.
Bauer AM; Hosie Quinn M; Lubitz SF; Flitter A; Ashare RL; Leone FT; Gross R; Hitsman B; Schnoll R
Addict Behav; 2021 Jan; 112():106638. PubMed ID: 32911350
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Varenicline Adherence Among Cancer Patients Treated for Tobacco Dependence and its Association With Smoking Cessation.
Crawford G; Weisbrot J; Bastian J; Flitter A; Jao NC; Carroll A; Kalhan R; Leone F; Hitsman B; Schnoll R
Nicotine Tob Res; 2019 Jul; 21(8):1135-1139. PubMed ID: 29955828
[TBL] [Abstract][Full Text] [Related]
4. Correlates of Adherence to Varenicline Among HIV+ Smokers.
Shelley D; Tseng TY; Gonzalez M; Krebs P; Wong S; Furberg R; Sherman S; Schoenthaler A; Urbina A; Cleland CM
Nicotine Tob Res; 2015 Aug; 17(8):968-74. PubMed ID: 26180221
[TBL] [Abstract][Full Text] [Related]
5. Measures and predictors of varenicline adherence in the treatment of nicotine dependence.
Peng AR; Morales M; Wileyto EP; Hawk LW; Cinciripini P; George TP; Benowitz NL; Nollen NL; Lerman C; Tyndale RF; Schnoll R
Addict Behav; 2017 Dec; 75():122-129. PubMed ID: 28728040
[TBL] [Abstract][Full Text] [Related]
6. Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.
Peng AR; Schnoll R; Hawk LW; Cinciripini P; George TP; Lerman C; Tyndale RF
Drug Alcohol Depend; 2018 Sep; 190():72-81. PubMed ID: 29986268
[TBL] [Abstract][Full Text] [Related]
7. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo.
Littlewood RA; Claus ED; Wilcox CE; Mickey J; Arenella PB; Bryan AD; Hutchison KE
Psychopharmacology (Berl); 2017 Dec; 234(23-24):3417-3429. PubMed ID: 28889258
[TBL] [Abstract][Full Text] [Related]
8. Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.
Wells QS; Freiberg MS; Greevy RA; Tyndale RF; Kundu S; Duncan MS; King S; Abney L; Scoville E; Beaulieu DB; Gatskie V; Tindle HA
Nicotine Tob Res; 2018 Nov; 20(12):1489-1496. PubMed ID: 29059367
[TBL] [Abstract][Full Text] [Related]
9. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms.
Rohsenow DJ; Tidey JW; Martin RA; Colby SM; Swift RM; Leggio L; Monti PM
Addiction; 2017 Oct; 112(10):1808-1820. PubMed ID: 28498504
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.
Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G;
Lancet HIV; 2018 Mar; 5(3):e126-e135. PubMed ID: 29329763
[TBL] [Abstract][Full Text] [Related]
11. Improved clinical outcomes among persons with HIV who quit smoking.
Lubitz SF; Flitter A; Ashare RL; Thompson M; Leone F; Gross R; Schnoll R
AIDS Care; 2020 Oct; 32(10):1217-1223. PubMed ID: 31847536
[TBL] [Abstract][Full Text] [Related]
12. Cancer-related disease factors and smoking cessation treatment: Analysis of an ongoing clinical trial.
Carroll AJ; Veluz-Wilkins AK; Blazekovic S; Kalhan R; Leone FT; Wileyto EP; Schnoll RA; Hitsman B
Psychooncology; 2018 Feb; 27(2):471-476. PubMed ID: 28636795
[TBL] [Abstract][Full Text] [Related]
13. Combining Text Messaging and Telephone Counseling to Increase Varenicline Adherence and Smoking Abstinence Among Cigarette Smokers Living with HIV: A Randomized Controlled Study.
Tseng TY; Krebs P; Schoenthaler A; Wong S; Sherman S; Gonzalez M; Urbina A; Cleland CM; Shelley D
AIDS Behav; 2017 Jul; 21(7):1964-1974. PubMed ID: 27605365
[TBL] [Abstract][Full Text] [Related]
14. Quitting Failure and Success With and Without Using Medication: Latent Classes of Abstinence and Adherence to Nicotine Monotherapy, Combination Therapy, and Varenicline.
McCarthy DE; Versella MV
Nicotine Tob Res; 2019 Oct; 21(11):1488-1495. PubMed ID: 30107419
[TBL] [Abstract][Full Text] [Related]
15. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
16. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
17. Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis.
Wu Q; Gilbody S; Peckham E; Brabyn S; Parrott S
Addiction; 2016 Sep; 111(9):1554-67. PubMed ID: 27043328
[TBL] [Abstract][Full Text] [Related]
18. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial.
Tulloch HE; Pipe AL; Els C; Clyde MJ; Reid RD
BMC Med; 2016 Jun; 14():80. PubMed ID: 27233840
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence.
Schnoll R; Leone F; Veluz-Wilkins A; Miele A; Hole A; Jao NC; Paul Wileyto E; Carroll AJ; Kalhan R; Patel J; Langer C; Lubitz SF; Hitsman B
Psychooncology; 2019 Mar; 28(3):561-569. PubMed ID: 30680852
[TBL] [Abstract][Full Text] [Related]
20. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
